| Literature DB >> 30572603 |
Jorge Iván Castillo-Arellano1,2, Juan Carlos Gómez-Verjan3, Nadia A Rojano-Vilchis4, Myrna Mendoza-Cruz5, Manuel Jiménez-Estrada6, Héctor E López-Valdés7, Hilda Martínez-Coria8, Roger Gutiérrez-Juárez9, Claudia González-Espinosa10, Ricardo Reyes-Chilpa11, Isabel Arrieta-Cruz12.
Abstract
Cacalolides are a kind of sesquiterpenoids natural compounds synthesized by Psacalium decompositum (A. Gray) H. Rob. & Brettell or Psacalium peltatum (Kunth) Cass. Antioxidant and hypoglycemic effects have been found for cacalolides such as cacalol, cacalone or maturine, however, their effects on inflammatory processes are still largely unclear. The main aim of this study was to investigate the biological activities of secondary metabolites from P. decompositum and P. peltatum through two approaches: (1) chemoinformatic and toxicoinformatic analysis based on ethnopharmacologic background; and (2) the evaluation of their potential anti-inflammatory/anti-allergic effects in bone marrow-derived mast cells by IgE/antigen complexes. The bioinformatics properties of the compounds: cacalol; cacalone; cacalol acetate and maturin acetate were evaluated through Osiris DataWarrior software and Molinspiration and PROTOX server. In vitro studies were performed to test the ability of these four compounds to inhibit antigen-dependent degranulation and intracellular calcium mobilization, as well as the production of reactive oxygen species in bone marrow-derived mast cells. Our findings showed that cacalol displayed better bioinformatics properties, also exhibited a potent inhibitory activity on IgE/antigen-dependent degranulation and significantly reduced the intracellular calcium mobilization on mast cells. These data suggested that cacalol could reduce the negative effects of the mast cell-dependent inflammatory process.Entities:
Keywords: Psacalium decompositum; Psacalium peltatum; cacalol; calcium channels; inflammation; maturin; reactive oxygen species
Mesh:
Substances:
Year: 2018 PMID: 30572603 PMCID: PMC6321304 DOI: 10.3390/molecules23123367
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of cacalolides from two species of matarique (P. decompositum and P. peltatum): (A) cacalol; (B) cacalone; (C) cacalol acetate; (D) maturin acetate.
Estimated physicochemical, pharmacokinetic, medicinal chemistry and toxicoinformatic properties of cacalolides *.
| Cacalol | Cacalone | Cacalol Acetate | Maturin Acetate | ||
|---|---|---|---|---|---|
|
| Log P | 3.65 | 2.56 | 3.42 | 3.20 |
| Log S | −5.56 | −4.04 | −4.34 | −5.09 | |
| TPSA | 33.37 A | 50.44 A | 39.44 A | 65.74 A | |
| MW | 230.30 g/mol | 246.30 g/mol | 272.34 g/mol | 312.34 g/mol | |
| RB | 0 | 0 | 2 | 5 | |
| BD | 1 | 1 | 0 | 0 | |
| BA | 2 | 3 | 3 | 5 | |
| Molar refractivity | 70.64 | 68.83 | 78.26 | 86.20 | |
|
| GI absorption | High | High | High | High |
| BBB permeable | Yes | Yes | Yes | Yes | |
| P-gp substrate | Yes | Yes | No | No | |
| CYP1A2 inhibitor | Yes | No | No | Yes | |
| CYP2C19 inhibitor | Yes | Yes | Yes | Yes | |
| CYP2C9 inhibitor | No | No | No | Yes | |
| CYP2D6 Inhibitor | No | No | No | No | |
| CYP3A4 inhibitor | No | No | No | Yes | |
| Log Kp (Skin permeation) | −4.62 cm/s | −6.14 cm/s | −5.79 cm/s | −5.99 cm/s | |
|
| Lipinski | Yes | Yes | Yes | Yes |
| Ghose | Yes | Yes | Yes | Yes | |
| Bioavailability Score | 0.55 | 0.55 | 0.55 | 0.55 | |
| Lead-likeness | No, 2 Violations | No, 1 violation | Yes | Yes | |
| Synthetic accessibility | 2.75 | 4.32 | 4.72 | 3.77 | |
|
| Toxicity Class | 5 | 4 | 5 | 5 |
| Mutagenic | None | None | None | None | |
| Tumorigenic | None | None | None | None | |
| Irritant | None | None | High | None | |
| Reproductive effects | None | None | None | None | |
| Possible Toxic Target | None | None | None | Amine oxidase prostaglandin G/H synthase 1 | |
| Toxic Fragments | None | None | None | None |
* Theoretical values. Abbreviations: GI—Gastrointestinal absorption; BBB—Blood brain barrier; P—gp-Glycoprotein P; GPCR—Receptor of protein G; MW—Molecular weight; RB—Rotatable bonds; BD—Number of H donors; BA—Number of H-bond acceptors; TPSA—Total polar surface area.
Enrichment analysis (GO and Pathway) of the main 50 targets that interact with cacalol using network pharmacology approaches *.
| Compound | Pathway or GO Term | Count | Data Base | |
|---|---|---|---|---|
| Cacalol | Innate immune system (hsa-168249) | 24 | 2.43 × 10−20 | Reactome |
| VEGFA-VEGFR2 pathway (hsa-4420097) | 12 | 4.42 × 10−12 | Reactome | |
| Fc epsilon receptor signaling (hsa-2454202) | 12 | 4.42 × 10−12 | Reactome | |
| PI3K-Akt pathway (hsa04151) | 12 | 4.91 × 10−12 | KEGG 1 | |
| MAPK signaling pathway (hsa04010) | 11 | 7.89 × 10−12 | KEGG 1 | |
| Protein kinase activity (GO:0004672) | 26 | 1.58 × 10−31 | GO-MF 2 |
* Theoretical values. 1 Kyoto Encyclopedia of genes and genomes. 2 Gene Ontology-Molecular Function.
Figure 2Cacalolides inhibit degranulation stimulated by antigen in bone marrow-derived mast cells. Effect of cacalol (A) cacalone (B) cacalol acetate (C) and maturine acetate (D) pre-treatment on DNP-HSA-induced degranulation, n = 3. * p ≤ 0.05.
Figure 3Cacalol inhibits intracellular calcium influx stimulated by FcεRI receptor in bone marrow-derived mast cells. (A) Representative trace of intracellular calcium rise in cells pre-treated with either vehicle or different concentrations of cacalol; (B) Rate of increase of [Ca2+]i; (C) Maximum concentration of [Ca2+]i. n = 3. * p ≤ 0.05.
Figure 4Cacalol inhibits FcεRI-triggered degranulation in BMMCs as the antioxidant Trolox does. * p ≤ 0.05.